|Dr. James S. Kuo M.B.A., M.D.||Independent Chairman||N/A||N/A||1965|
|Dr. Jennifer Lynne Bath Ph.D.||CEO, Pres & Director||1.06M||N/A||N/A|
|Ms. Lisa Helbling||Chief Financial Officer||438.46k||N/A||N/A|
|Dr. Yasmina Noubia Abdiche Ph.D.||Chief Scientific Officer||30.49k||N/A||N/A|
|Dr. Stefan Lang||Chief Bus. Officer||219.58k||N/A||N/A|
|Mr. David E. Orton||Chief Operating Officer||N/A||N/A||N/A|
|Ms. Lauren Smith||VP of Marketing and Sales||N/A||N/A||N/A|
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune and naive phage display production and screening; hybridoma production with screening and clone-picking; transgenic animals and multi-species antibody discovery; antibody characterization studies, such as affinity measurements, functional assays and epitope mapping, and binning; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA synthesis and cloning, protein and antibody downstream processing; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; and cryopreservation. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
ImmunoPrecise Antibodies Ltd.’s ISS Governance QualityScore as of April 30, 2021 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 5; Compensation: 4.